Share this video  

ESMO 2023 | KEYNOTE-522: 5-year follow-up of pembrolizumab in triple-negative breast cancer

Peter Schmid, FRCP, MD, PhD, Barts Cancer Institute, London, UK, discusses 5-year follow-up data from the Phase III KEYNOTE-522 (NCT03036488) trial which aimed to investigate pembrolizumab plus chemotherapy as neoadjuvant therapy, and pembrolizumab as adjuvant therapy, in patients with triple-negative breast cancer. It was previously reported that this pembrolizumab regimen resulted in statistically significant improvements in pathological complete response (pCR) and event-free survival (EFS). The 5-year follow up data confirm these earlier findings: the 60-month EFS rates were 81.3% in the pembrolizumab and chemotherapy arm, and 72.3% in the chemotherapy and placebo arm. The benefit with pembrolizumab was consistent across pre-specified subgroups. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.